Literature DB >> 35800283

Suppressing the activity of CXCR4 down-regulates the expression of renal fibrosis related genes in primary glomerular cells.

Shaofan Hu1, Hong Liu1, Qun Li1, Qiang Yu1, Xiaoqing Liu1, Jin Xu1, Rui Fu1.   

Abstract

Background: C-X-C chemokine receptor type 4 (CXCR4) has a certain effect on renal fibrosis, and there are few specific studies in cells. We want to investigate the impact of suppressing CXCR4 activity on the expression of renal fibrosis-related genes in primary glomerular endothelial cells, mesangial cells, and podocytes.
Methods: Immunofluorescence assays were used to determine the purity of isolated glomerular endothelial cells, mesangial cells, and podocytes. CXCR4 knockdown cell lines were established by transfecting the short hairpin (sh)RNA against CXCR4. T140 and AMD3100 were used to inhibit the activity of CXCR4. LY294002 was used to inhibit the activity of phosphoinositide 3-kinase (PI3K). The mRNA expression of CXCR4 was determined by real-time quantitative reverse transcription polymerase chain reaction (qRT-PCR). The protein expression of CXCR4, collagen IV, matrix metallopeptidase (MMP)-9, PI3K, Rac1, and vascular cell adhesion protein 1 (VCAM-1) was evaluated by Western blot analysis.
Results: High purity was observed on isolated primary glomerular endothelial cells and podocytes. However, the purity of isolated mesangial cells was relatively low. The mRNA expression of CXCR4 was significantly suppressed by the transfection of shRNA. Compared to control cells, the expression of CXCR4, collagen IV, MMP-9, PI3K, Rac1, and VCAM-1 were dramatically downregulated in cell lines transfected with shRNA against CXCR4. Furthermore, cell lines treated with T140, AMD3100, or LY294002 also showed downregulated expression of these proteins compared to untreated cells. No significant differences were observed in the protein expression of these proteins between control cells and cells transfected with the shRNA negative control (NC). Conclusions: Suppressing the activity of CXCR4 downregulated the expression of renal fibrosis-related genes in primary glomerular cells, even under a non-inflammatory state. 2022 Translational Pediatrics. All rights reserved.

Entities:  

Keywords:  AMD3100; C-X-C chemokine receptor type 4 (CXCR4); T140; glomerulus; renal fibrosis

Year:  2022        PMID: 35800283      PMCID: PMC9253943          DOI: 10.21037/tp-22-157

Source DB:  PubMed          Journal:  Transl Pediatr        ISSN: 2224-4336


Introduction

Renal fibrosis is defined as excessive growth, sclerosis, or scarring of kidney tissue due to excessive accumulation of extracellular matrix components, such as collagens. Severe cases of renal fibrosis may result in renal dysfunction (1). Renal fibrosis can be induced by almost all kinds of chronic renal diseases or injuries, such as sustained infections, autoimmune reactions, anaphylaxis, chemical injuries, radiation, and mechanical injuries (2). Chemokines are peptides with molecular weight ranging from 8 to 12 kDa, and are named for its chemotaxis against leukocytes. Chemokines have been reported to be involved in the development and progression of fibrosis by recruiting myofibroblasts, macrophages, and other effector cells to the site of injury (3,4). It has been demonstrated that pulmonary fibrosis can be significantly ameliorated by downregulating the expression chemokines, such as C-C motif chemokine ligand (CCL)2 and CCL3, or by blocking their receptors (5-7). In addition, the expression of fibrosis inducers, such as interleukin (IL)-4 and IL-13, could be suppressed by blocking the down-stream signaling pathways of CCL3/CCL2 (8,9). These reports verified the significance of chemokines in fibrosis. The C-X-C chemokine receptor (CXCR)4 is the receptor of CXCL12 (SDF1) and the main function of CXCL12/CXCR4 is to regulate the transport of hematopoietic cells and secondary lymphoid tissue structures (10), which play an important role in the growth and development of renal vessels (11). A study has shown that CXCR4 is a potential target for preventing renal fibrosis in patients with nephrolithiasis (12). Under renal ischemia, the expression of CXCR4 is elevated (13). Recently, CXCL12/CXCR4 was shown to promote the progression of renal fibrosis in unilateral ureteral ligated mice and rats with chronic transplanted kidney disease (14,15). However, the impact of CXCR4 on renal fibrosis has only been reported in animal experiments, which lacked fundamental investigations on a cellular level. Moreover, renal fibrosis is a common pathophysiological change after the end-stage of chronic kidney disease. Inflammation also plays an important role in renal fibrosis, but non-inflammatory factors (such as ischemia and hypoxia) may also lead to renal fibrosis in the course of renal fibrosis. Therefore, we explore the effect of CXCR4 gene on renal fibrosis from the perspective of non-inflammation. Apart from blood cells and immune cells, the glomeruli consists of glomerular basement membrane, mesangial matrix, glomerular endothelial cells, mesangial cells, and podocytes. Podocytes are targets of inflammatory and non-inflammatory injury in glomerular diseases, when podocytes are stimulated by various pathologies, it leads to the fusion and disappearance of podocytes and the abnormal number, shape and density of podocytes. The changes of pore membrane and cytoskeleton proteins destroy the integrity of glomerular filtration barrier and function, and cause mesangial cell proliferation and extracellular matrix metabolism disorder, resulting in glomerulosclerosis. The present study suppressed the activity of CXCR4 in the glomerular endothelial cells, mesangial cells, and podocytes by transfecting a short hairpin (sh)RNA or utilizing the CXCR4 inhibitor, to explore the impacts of CXCR4 suppression on the expression of fibrosis-related genes. This investigation provided novel insights into the regulatory properties of CXCR4 in glomerular cells under a non-inflammatory state. We present the following article in accordance with the MDAR and ARRIVE reporting checklists (available at https://tp.amegroups.com/article/view/10.21037/tp-22-157/rc).

Methods

Isolation and culture of primary glomerular endothelial cells, mesangial cells, and podocytes

A protocol was prepared before the study without registration. Animal experiments were performed under a project license (No. 2020052701) granted by ethics committee of Jiangxi Provincial Children’s Hospital, in compliance with Jiangxi Provincial Children’s Hospital institutional guidelines for the care and use of animals. Mouse were sacrificed and the kidneys were isolated and placed into Hank’s medium containing penicillin and streptomycin. Mouse purchased from Hunan slake Jingda experimental animal Co., Ltd. [License No: SCXK(Xiang)2021-0002], age 26-30 days. The kidney capsule was removed and the renal cortex was clipped into pieces. The glomerular endothelial cells were digested using 0.1% collagenase II solution, and the mesangial cells and podocytes were digested with 0.1% collagenase IV solution. The digestion steps were terminated by addition of complete medium. The digested tissues were percolated through a 100-µm filter, followed by centrifugation at 1,000 rpm for 5 minutes. Cells were collected and cultured using the corresponding medium. The culture medium for glomerular endothelial cells was DF12 containing 20% fetal bovine serum (FBS), penicillin, streptomycin, and vascular endothelial growth factor (VEGF). Mesangial cells were cultured in R1640 medium supplemented with 15% FBS, penicillin, streptomycin, and ITS (100×). Podocytes were cultured in KI medium and 3T3 medium at a ratio of 1:1. The KI medium contained DF12, HEPES (10 mM), penicillin, streptomycin, and ITS (100×). The 3T3 medium contained DMEM, 20% FBS, HEPES (10 mM), penicillin, streptomycin, glutamine (100×), and sodium pyruvate (1 mM).

Immunofluorescence assay

Treated cells were washed with phosphate buffered saline (PBS) solution, fixed with 4% paraformaldehyde, and incubated with the following primary antibodies: rabbit anti-CD34, anti-desmin, anti-nephrin, and anti-WT-1. Cells were then incubation with the appropriate secondary antibody conjugated to DAPI (a blue nuclear marker). Negative control staining was performed by omitting the primary antibody. The stained cells were observed using a fluorescence microscope.

Quantitative real-time polymerase chain reaction (qRT-PCR)

Total RNA was extracted from the cells using TRIzol reagent (Thermo Fisher, Massachusetts, USA) according to the manufacturer’s instructions. Transcription of cDNA from RNA using a SuperScript III kit (Takara, Tokyo, Japan). The relative expression of the detected proteins was detected using SYBR green quantitative PCR kit (Takara, Tokyo, Japan). Glyceraldehyde 3-phosphate dehydrogenase (GADPH) was used as the negative control. qRT-PCR was performed using the ABI Prism 7500 Fast Sequence Detection System (Applied Biosystems). The 2-ΔΔCt method was used to calculate and quantify the relative expression levels. The primer sequences used are shown in .
Table 1

The sequences of primers for CXCR4 and GAPDH

Primer IDSequencesLength of the primer (bp)Length of the product (bp)Annealing temperature (℃)
CXCR4 FGGGGTCATCAAGCAAGG179056.7
CXCR4 RCAGGCAACAGTGGAAGAAGG20
GAPDH FTCAACGGCACAGTCAAGG1835757.8
GAPDH RTGAGCCCTTCCACGATG17

CXCR4, C-X-C chemokine receptor type 4; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; F, forward; R, reverse.

CXCR4, C-X-C chemokine receptor type 4; GAPDH, glyceraldehyde 3-phosphate dehydrogenase; F, forward; R, reverse.

Transfection

The lentivirus containing the shRNA against CXCR4 (sh-CXCR4) and the negative (blank) control (shNC) was purchased from Xiamen Lifeint Co., Ltd. The lentivirus was transfected into the cells with Lipofectamine 3000 to establish the CXCR4 knockdown cell lines.

Western blot analysis

Cells were lysed with RIPA lysis buffer containing protease and phosphatase inhibitors, and then centrifuged at 14,000 rpm for 20 minutes at 4 ℃. The total concentration of proteins was detected using the BCA assay kit (Thermo Fisher Scientific, Rockford, IL, USA). Approximately 80 µg of protein was isolated from each sample by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene fluoride (PVDF) membranes (Millipore, Massachusetts, USA). The samples were incubated with 5% skim milk for 90 minutes to remove the non-specific binding proteins. Membranes were then incubated with primary rabbit antibodies against CXCR4, collagen IV, MMP-9, PI3K, Rac1, or VCAM-1 (1:1,000, Abcam, Massachusetts, USA) at 4 ℃ overnight. Subsequently washed with 0.1% Tris buffered saline Tween (TBST), the cell membranes were incubated with secondary antibodies and the immuno-reactive bands were observed by chemiluminescence using an ECL kit (Beyotime, Shanghai, China). The specific bands were analyzed using ImageJ software.

Statistical analysis

All statistical analyses were performed using SPSS 19.0 software. All data are presented as mean ± standard deviation. Student’s t-tests were used for inter-group comparisons. For comparisons of 3 or more groups, one-way analysis of variance (ANOVA) was conducted, followed by the Bonferroni post-hoc test. A P value <0.05 was considered statistically significant.

Results

The identification of primary glomerular endothelial cells, mesangial cells, and podocytes

Primary glomerular endothelial cells, mesangial cells, and podocytes were isolated and the purity was confirmed by immunofluorescence staining for CD34, desmin, and nephrin and WT-1, respectively (). CD34 was expressed on almost all the glomerular endothelial cells, and nephrin and WT-1 were expressed on almost all the podocytes, indicating a relatively high purity for isolated primary glomerular endothelial cells and podocytes. In contrast, desmin was only expressed on a portion of the isolated mesangial cells, indicating relatively low purity for the isolated mesangial cells.
Figure 1

The isolated primary glomerular endothelial cells, mesangial cells, and podocytes were identified by immunofluorescence assays. Blue represents the nucleus dyed by DAPI. Red or green represents the target proteins.

The isolated primary glomerular endothelial cells, mesangial cells, and podocytes were identified by immunofluorescence assays. Blue represents the nucleus dyed by DAPI. Red or green represents the target proteins.

Suppressing the activity of CXCR4 downregulated the expression of renal fibrosis-related genes in primary glomerular cells

To confirm the transfection efficacy, qRT-PCR and Western blot assays were performed to assess the expression of CXCR4. As shown in , compared to control cells, glomerular endothelial cells (HRGECs), mesangial cells (HRMCs), and podocytes (HRPs) transfected with the sh-CXCR4 showed significantly suppressed expression of CXCR4, indicating a successful knockdown of CXCR4 in all three cell lines by sh-CXCR4 (P<0.05).
Figure 2

The expression of CXCR4 in the glomerular endothelial cells, mesangial cells, and podocytes transfected with sh-CXCR4 was evaluated by qRT-PCR and Western Blot assays. *, P<0.05, vs. control; #, P<0.05, shCXCR4-1 vs. shNC. CXCR4, C-X-C chemokine receptor type 4; HRGEC, glomerular endothelial cells; HRMC, mesangial cells; HRP, podocytes; sh, short hairpin; qRT-PCR, quantitative real-time polymerase chain reaction; NC, negative control; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

The expression of CXCR4 in the glomerular endothelial cells, mesangial cells, and podocytes transfected with sh-CXCR4 was evaluated by qRT-PCR and Western Blot assays. *, P<0.05, vs. control; #, P<0.05, shCXCR4-1 vs. shNC. CXCR4, C-X-C chemokine receptor type 4; HRGEC, glomerular endothelial cells; HRMC, mesangial cells; HRP, podocytes; sh, short hairpin; qRT-PCR, quantitative real-time polymerase chain reaction; NC, negative control; GAPDH, glyceraldehyde 3-phosphate dehydrogenase. As shown in , Western blot analyses demonstrated that the expression of CXCR4, collagen IV, MMP-9, PI3K, Rac1, and VCAM-1 were dramatically downregulated in the cell lines transfected with sh-CXCR4. Furthermore, cell lines treated with T140, AMD3100, or LY294002 also showed markedly reduced expression of CXCR4, collagen IV, MMP-9, PI3K, Rac1, and VCAM-1 compared to untreated cells. No significant differences were observed in the expression levels of these proteins between control cells and cells transfected with shNC (P<0.05).
Figure 3

The expression of CXCR4, Collagen IV, MMP-9, PI3K, Rac1, and VCAM-1 was evaluated by Western blot assays. *, P<0.05, vs. control. CXCR4, C-X-C chemokine receptor type 4; MMP, matrix metallopeptidase; PI3K, phosphoinositide 3-kinase; Rac1, Ras-related C3 botulinum toxin substrate 1; VCAM-1, vascular cell adhesion protein 1; sh, short hairpin; NC, negative control; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

The expression of CXCR4, Collagen IV, MMP-9, PI3K, Rac1, and VCAM-1 was evaluated by Western blot assays. *, P<0.05, vs. control. CXCR4, C-X-C chemokine receptor type 4; MMP, matrix metallopeptidase; PI3K, phosphoinositide 3-kinase; Rac1, Ras-related C3 botulinum toxin substrate 1; VCAM-1, vascular cell adhesion protein 1; sh, short hairpin; NC, negative control; GAPDH, glyceraldehyde 3-phosphate dehydrogenase.

Discussion

Tissue fibrosis is the process of repair following tissue injury, and if uncontrolled, this can contribute to sustained fibrosis which is characterized by destruction of the tissue structure and dysfunction of the organ (16). Renal fibrosis is the common denouement of various chronic renal diseases, which is mainly caused by the imbalance between the synthesis and the degradation of the extracellular matrix. Renal fibrosis is characterized by abnormal accumulation of extracellular matrix, progressive changes in the structure of the kidney, and sustained dysfunction of the kidneys. To date, there are no effective radical therapies for the treatment of clinical renal fibrosis, with current therapies concentrating on delaying the progression of the disease. Therefore, understanding the molecular mechanisms underlying renal interstitial fibrosis is crucial for the development of potential targeted therapies to reverse renal interstitial fibrosis. CXCR4 has been shown to play an important role in the pathological process of autoimmune diseases, including the fibrosis of the lungs and liver (17). Under the normal healthy state, CXCR4 is expressed at relatively low levels in renal tissues. However, under the pathological state, such as IgA nephropathy and focal stage glomerulosclerosis, the expression of CXCR4 is significantly elevated (18). In addition, CXCR4 has been shown to promote the chronic progression of renal fibrosis (14,19). In the present study, the expression levels of fibrosis-related genes (including collagen IV, MMP-9, and VCAM-1), CXCR4, and the downstream regulatory elements (including PI3K and Rac1) were evaluated in the sh-CXCR4 transfected isolated primary glomerular endothelial cells, mesangial cells, and podocytes to verify the function of CXCR4 in the development and progression of renal fibrosis at a cellular level. Collagen IV is the main component of glomerular basement membrane and constitutes the classical network structure in the kidney, together with laminin, proteoglycan, and paraplegic protein (20). Tissue repair and chronic inflammation can induce excessive accumulation of extracellular matrix components, such as collagen, which in turn, can be degraded by various MMPs. MMP9 is a classic MMP involved in the development and progression of fibrosis. Although the progression of fibrosis is accompanied by upregulation of MMP9, both promoting and inhibitory effects have been reported for MMP9 in the regulation of fibrosis (21,22). VCAM-1 is involved in mediating the adhesion and signal transduction of leukocytes and is highly expressed in the kidneys. VCAM-1 has also been shown to play an important role in the development of renal inflammation (23). In the present study, suppressing the activity of CXCR4 in the isolated primary glomerular endothelial cells, mesangial cells, and podocytes by incubating with CXCR4 inhibitors (T140 and AMD3100) significantly suppressed the expression of collagen IV, MMP-9, and VCAM-1. Similar results were observed when PI3K was inactivated by incubating cells with LY294002. A recent report has emphasized the positive correlation between CXCR4 and the inflammatory reaction in the kidneys, and indicated that CXCR4 inhibitors can ameliorate the symptoms of renal fibrosis by inhibiting renal inflammation through suppressing the recruitment of immune cells (24). In addition, it has also been reported that under the inflammatory state, CXCR4 located on macrophages promoted the progression of renal fibrosis via various pathways. The recruitment of macrophages could be significantly suppressed by knocking down the expression of CXCR4 on the macrophages, resulting in amelioration of renal fibrosis (25-27). In contrast to the glomerulus in the kidney, the isolated primary glomerular cells used in the present study were not influenced by other immune cells and inflammatory factors, and this is the main difference between the present study and previous reports. This investigation demonstrated that renal fibrosis-related genes could be regulated by CXCR4 and the downstream signaling pathways in the glomerulus, even in the absence of inflammation. PI3K can be activated by the Gβγ subunit bound by CXCR4, which further activates Rac2 to form the Rac/Cdc42 complex, Finally, the chemotaxis reaction will be triggered (28). It has also been reported that P-Rex1 can be activated by the Gβγ subunit, which activates Rac1 to bind GTP independently of PI3K (29). The present study showed that the expression of PI3K and Rac1 was significantly suppressed in the primary glomerular endothelial cells, mesangial cells, and podocytes by knocking down or inactivating CXCR4, and this was similar to the effects observed with the PI3K inhibitor. We speculate that in the glomerulus, PI3K/Rac is the downstream signaling pathway of CXCR4, which regulates the expression of fibrosis-related genes. The highest expression of CXCR4 is normally observed in the bone marrow lymphatics and the circulatory system. It is also highly expressed in the kidneys, the gastrointestinal tract, and the lungs (30). T140, an inhibitor of CXCR4, has been shown to specifically inhibit CXCR4 (31), and this may represent a promising targeted agent against CXCR4. The results of this investigation suggested that synergistic effects may be observed when combining inflammation inhibitory therapy with a CXCR4 inhibitor, and this may be a novel potential therapeutic regimen for the treatment of renal fibrosis. The article’s supplementary files as
  31 in total

Review 1.  Chemokines and their receptors: drug targets in immunity and inflammation.

Authors:  Antonella Viola; Andrew D Luster
Journal:  Annu Rev Pharmacol Toxicol       Date:  2008       Impact factor: 13.820

2.  Proteomics. Tissue-based map of the human proteome.

Authors:  Mathias Uhlén; Linn Fagerberg; Björn M Hallström; Cecilia Lindskog; Per Oksvold; Adil Mardinoglu; Åsa Sivertsson; Caroline Kampf; Evelina Sjöstedt; Anna Asplund; IngMarie Olsson; Karolina Edlund; Emma Lundberg; Sanjay Navani; Cristina Al-Khalili Szigyarto; Jacob Odeberg; Dijana Djureinovic; Jenny Ottosson Takanen; Sophia Hober; Tove Alm; Per-Henrik Edqvist; Holger Berling; Hanna Tegel; Jan Mulder; Johan Rockberg; Peter Nilsson; Jochen M Schwenk; Marica Hamsten; Kalle von Feilitzen; Mattias Forsberg; Lukas Persson; Fredric Johansson; Martin Zwahlen; Gunnar von Heijne; Jens Nielsen; Fredrik Pontén
Journal:  Science       Date:  2015-01-23       Impact factor: 47.728

3.  CXC Chemokine Receptor Type 4 Antagonism Ameliorated Allograft Fibrosis in Rat Kidney Transplant Model.

Authors:  Xun-Feng Zou; Jian-Hua Gu; Zi-Lin Cui; Yi-Wei Lu; Chuan Gu
Journal:  Exp Clin Transplant       Date:  2017-06-05       Impact factor: 0.945

4.  Critical role for the chemokine MCP-1/CCR2 in the pathogenesis of bronchiolitis obliterans syndrome.

Authors:  J A Belperio; M P Keane; M D Burdick; J P Lynch; Y Y Xue; A Berlin; D J Ross; S L Kunkel; I F Charo; R M Strieter
Journal:  J Clin Invest       Date:  2001-08       Impact factor: 14.808

5.  Involvement of MMP-9 in peribiliary fibrosis and cholangiocarcinogenesis via Rac1-dependent DNA damage in a hamster model.

Authors:  Suksanti Prakobwong; Puangrat Yongvanit; Yusuke Hiraku; Chawalit Pairojkul; Paiboon Sithithaworn; Porntip Pinlaor; Somchai Pinlaor
Journal:  Int J Cancer       Date:  2010-12-01       Impact factor: 7.396

6.  The CXCL12 (SDF-1)/CXCR4 axis is essential for the development of renal vasculature.

Authors:  Yoshitsugu Takabatake; Tatsuki Sugiyama; Hiroshi Kohara; Taiji Matsusaka; Hidetake Kurihara; Pandelakis A Koni; Yasuyuki Nagasawa; Takayuki Hamano; Isao Matsui; Noritaka Kawada; Enyu Imai; Takashi Nagasawa; Hiromi Rakugi; Yoshitaka Isaka
Journal:  J Am Soc Nephrol       Date:  2009-05-14       Impact factor: 10.121

7.  Expression of SDF-1/CXCR4 in injured human kidneys.

Authors:  Danny Lotan; Natalia Sheinberg; Jury Kopolovic; Benjamin Dekel
Journal:  Pediatr Nephrol       Date:  2007-10-31       Impact factor: 3.714

8.  Combination of vessel-targeting agents and fractionated radiation therapy: the role of the SDF-1/CXCR4 pathway.

Authors:  Fang-Hsin Chen; Sheng-Yung Fu; Ying-Chieh Yang; Chun-Chieh Wang; Chi-Shiun Chiang; Ji-Hong Hong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-04-16       Impact factor: 7.038

9.  Origin and function of myofibroblasts in kidney fibrosis.

Authors:  Valerie S LeBleu; Gangadhar Taduri; Joyce O'Connell; Yingqi Teng; Vesselina G Cooke; Craig Woda; Hikaru Sugimoto; Raghu Kalluri
Journal:  Nat Med       Date:  2013-06-30       Impact factor: 53.440

10.  Correlation between ICAM1 and VCAM1 gene polymorphisms and histopathological changes in kidney allograft biopsies.

Authors:  Leszek Domanski; Karolina Kłoda; Andrzej Pawlik; Magda Wisniewska; Ewa Kwiatkowska; Mateusz Kurzawski; Krzysztof Safranow; Kazimierz Ciechanowski
Journal:  Arch Med Sci       Date:  2012-06-28       Impact factor: 3.318

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.